ClinicalTrials.gg
CompletedNCT02097745Updated Nov 3, 2016Results posted

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

A Phase 3 interventional study of methotrexate and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 97 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
13th of 63
341 · median 159
Started
2004
the only one that year
Phase 3
27 of 63
1 open now
Registered
48th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is the only one that started in 2004, is one of 27 in phase 3, and was the 48th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients 18-80 years of age with active RA;
  • patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
  • eligible for re-treatment, based on clinical symptoms;
  • patients of must be using reliable methods.

Exclusion criteria

Exclusion Criteria:

  • patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;
  • current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
  • development of any new to receiving MabThera;
  • women who are pregnant or breast-feeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    MabThera/Rituxan

    Drug: methotrexate · Drug: rituximab [MabThera/Rituxan]

Interventions

  • a 10-25 mg stable dose given orally or parenterally throughout study

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1 g given by intravenous infusion on Days 1 and 15 of each treatment course

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response

    A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \[symptom-free and no arthritis symptoms\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

Secondary outcomes

  1. Change From Baseline in the Disease Activity Score 28 (DAS28)

    The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  2. Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission

    The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Low disease activity was defined as a DAS28 score ≤ 3.2. DAS28 remission was defined as a DAS28 score \< 2.6. The first retreatment may have occurred in the precursor study WA17042.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  3. Percentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses

    Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \> 3.2 to ≤ 5.1, a change from baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \> 5.1, a change from baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \> 3.2. The first retreatment may have occurred in the precursor study WA17042.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  4. Change From Baseline in the American College of Rheumatology n (ACRn) Response

    The ACRn response was defined as each participant's least favorable percentage change from Baseline in 3 measures, tender joint count, swollen joint count (28 assessed joints), and improvement score achieved in at least 3 of the 5 remaining ACR parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity, right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain, right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). A higher change percentage indicates greater improvement from Baseline. The ACRn response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  5. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  6. Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey

    The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  7. Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

    The FACIT-F is a 13-item participant self-reporting questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.

    Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  8. Percentage of Participants With no Radiographic Progression From Baseline to Year 5

    Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. Data is reported for 2 groups.

    Time frame: Baseline to Year 5

  9. Change From Baseline in the Total Genant-modified Sharp Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Time frame: Baseline to Year 5

  10. Change From Baseline in the Genant-modified Sharp Erosion Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Time frame: Baseline to Year 5

  11. Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score joint space narrowing of 0-4 (9 gradations) is assigned to 13 joints in each hand and 6 joints in each foot. The maximum joint space narrowing score is 38 x 4.0 = 152 which is normalized to a score of 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Time frame: Baseline to Year 5

  12. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement. Data is reported for 2 groups.

    Time frame: Baseline to Year 5

07

Results

Posted Nov 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started335
Completed157
Not completed178
Withdrew: Adverse event25
Withdrew: Death16
Withdrew: Failure to return14
Withdrew: Administrative/other27
Withdrew: Reason not specified96

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20 (ACR20) Response

A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \[symptom-free and no arthritis symptoms\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response
Percentage of participantsRituximab
Retreatment 1 (n = 320)67.5
Retreatment 2 (n = 267)74.9
Retreatment 3 (n = 234)73.9
Retreatment 4 (n = 175)67.4
Retreatment 5 (n = 136)69.9
Retreatment 6 (n = 92)72.8
SecondaryChange From Baseline in the Disease Activity Score 28 (DAS28)

The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Mean · Units on a scale
Change From Baseline in the Disease Activity Score 28 (DAS28)
Units on a scaleRituximab
Retreatment 1 (n = 304)-2.32 ± 1.336
Retreatment 2 (n = 258)-2.77 ± 1.302
Retreatment 3 (n = 227)-3.01 ± 1.388
Retreatment 4 (n = 168)-3.05 ± 1.537
Retreatment 5 (n = 132)-3.15 ± 1.536
Retreatment 6 (n = 87)-2.96 ± 1.540
SecondaryPercentage of Participants With DAS28 Low Disease Activity and DAS28 Remission

The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Low disease activity was defined as a DAS28 score ≤ 3.2. DAS28 remission was defined as a DAS28 score \< 2.6. The first retreatment may have occurred in the precursor study WA17042.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission
Percentage of participantsRituximab
Retreatment 1: Low Disease Activity (n=314)17.2
Retreatment 1: Remission8.9
Retreatment 2: Low Disease Activity (n=265)27.9
Retreatment 2: Remission15.1
Retreatment 3: Low Disease Activity (n=234)36.8
Retreatment 3: Remission18.8
Retreatment 4: Low Disease Activity (n=172)33.7
Retreatment 4: Remission20.9
Retreatment 5: Low Disease Activity (n=135)36.3
Retreatment 5: Remission20.0
Retreatment 6: Low Disease Activity (n=90)33.3
Retreatment 6: Remission15.6
SecondaryPercentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses

Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \> 3.2 to ≤ 5.1, a change from baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \> 5.1, a change from baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \> 3.2. The first retreatment may have occurred in the precursor study WA17042.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses
Percentage of participantsRituximab
Retreatment 1: Good Response (n = 304)17.1
Retreatment 1: Moderate Response64.8
Retreatment 1: No Response18.1
Retreatment 2: Good Response (n = 258)27.5
Retreatment 2: Moderate Response64.3
Retreatment 2: No Response8.1
Retreatment 3: Good Response (n = 227)36.6
Retreatment 3: Moderate Response53.3
Retreatment 3: No Response10.1
Retreatment 4: Good Response (n = 168)33.9
Retreatment 4: Moderate Response58.9
Retreatment 4: No Response7.1
Retreatment 5: Good Response (n = 132)36.4
Retreatment 5: Moderate Response54.5
Retreatment 5: No Response9.1
Retreatment 6: Good Response (n = 87)33.3
Retreatment 6: Moderate Response59.8
Retreatment 6: No Response6.9
SecondaryChange From Baseline in the American College of Rheumatology n (ACRn) Response

The ACRn response was defined as each participant's least favorable percentage change from Baseline in 3 measures, tender joint count, swollen joint count (28 assessed joints), and improvement score achieved in at least 3 of the 5 remaining ACR parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity, right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain, right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). A higher change percentage indicates greater improvement from Baseline. The ACRn response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Mean · Percentage change
Change From Baseline in the American College of Rheumatology n (ACRn) Response
Percentage changeRituximab
Retreatment 1 (n = 320)32.04 ± 37.709
Retreatment 2 (n = 267)39.25 ± 35.494
Retreatment 3 (n = 234)39.89 ± 41.166
Retreatment 4 (n = 175)37.71 ± 43.201
Retreatment 5 (n = 136)37.59 ± 41.109
Retreatment 6 (n = 92)35.53 ± 38.650
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Mean · Units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Units on a scaleRituximab
Retreatment 1 (n = 320)-0.51 ± 0.569
Retreatment 2 (n = 267)-0.54 ± 0.569
Retreatment 3 (n = 234)-0.56 ± 0.601
Retreatment 4 (n = 175)-0.55 ± 0.603
Retreatment 5 (n = 136)-0.60 ± 0.647
Retreatment 6 (n = 92)-0.55 ± 0.653
SecondaryChange From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey

The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Mean · Units on a scale
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey
Units on a scaleRituximab
Retreatment 1: Physical Health (n = 249)7.383 ± 8.4618
Retreatment 1: Mental Health5.550 ± 12.0705
Retreatment 2: Physical Health (n = 255)6.018 ± 7.9757
Retreatment 2: Mental Health5.746 ± 10.7778
Retreatment 3: Physical Health (n = 220)6.206 ± 8.2326
Retreatment 3: Mental Health4.777 ± 10.1916
Retreatment 4: Physical Health (n = 167)5.660 ± 7.9137
Retreatment 4: Mental Health4.864 ± 10.2215
Retreatment 5: Physical Health (n = 124)5.038 ± 8.2643
Retreatment 5: Mental Health5.141 ± 11.8848
Retreatment 6: Physical Health (n = 88)5.214 ± 7.5370
Retreatment 6: Mental Health2.658 ± 9.8556
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

The FACIT-F is a 13-item participant self-reporting questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.

Time frame:
Baseline to the end of the retreatment period (up to 7 years, 6 months)
Reported as:
Mean · Units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
Units on a scaleRituximab
Retreatment 1 (n = 321)10.790 ± 10.7934
Retreatment 2 (n = 272)6.390 ± 9.1312
Retreatment 3 (n = 232)7.075 ± 9.8208
Retreatment 4 (n = 176)6.770 ± 10.4043
Retreatment 5 (n = 131)8.030 ± 10.4571
Retreatment 6 (n = 89)5.429 ± 9.4251
SecondaryPercentage of Participants With no Radiographic Progression From Baseline to Year 5

Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. Data is reported for 2 groups.

Time frame:
Baseline to Year 5
Reported as:
Number · Percentage of participants
Percentage of Participants With no Radiographic Progression From Baseline to Year 5
Percentage of participantsPlaceboRituximab
Percentage of Participants With no Radiographic Progression From Baseline to Year 521.5 (12.0 to 31.0)32.4 (23.0 to 41.0)
SecondaryChange From Baseline in the Total Genant-modified Sharp Score at Year 5

The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

Time frame:
Baseline to Year 5
Reported as:
Mean · Units on a scale
Change From Baseline in the Total Genant-modified Sharp Score at Year 5
Units on a scalePlaceboRituximab
Change From Baseline in the Total Genant-modified Sharp Score at Year 55.446 ± 8.47013.202 ± 6.5538
SecondaryChange From Baseline in the Genant-modified Sharp Erosion Score at Year 5

The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

Time frame:
Baseline to Year 5
Reported as:
Mean · Units on a scale
Change From Baseline in the Genant-modified Sharp Erosion Score at Year 5
Units on a scalePlaceboRituximab
Change From Baseline in the Genant-modified Sharp Erosion Score at Year 53.101 ± 4.89801.880 ± 4.4491
SecondaryChange From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5

The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score joint space narrowing of 0-4 (9 gradations) is assigned to 13 joints in each hand and 6 joints in each foot. The maximum joint space narrowing score is 38 x 4.0 = 152 which is normalized to a score of 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

Time frame:
Baseline to Year 5
Reported as:
Mean · Units on a scale
Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5
Units on a scalePlaceboRituximab
Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 52.344 ± 4.32631.322 ± 2.7831
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5

The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement. Data is reported for 2 groups.

Time frame:
Baseline to Year 5
Reported as:
Mean · Units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5
Units on a scalePlaceboRituximab
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5-0.408 ± 0.5348-0.540 ± 0.6521

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—14/140 (10%)112/140 (80%)
Rituximab—197/335 (58.8%)327/335 (97.6%)
Most frequent serious events
Showing 10 of 253
Most frequent serious events
EventPlaceboRituximab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/14023/335
FallInjury, poisoning and procedural complications3/14013/335
PneumoniaInfections and infestations0/14010/335
OsteoarthritisMusculoskeletal and connective tissue disorders0/14010/335
CellulitisInfections and infestations0/1406/335
Coronary artery diseaseCardiac disorders0/1405/335
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1405/335
Infusion related reactionGeneral disorders0/1405/335
GastroenteritisInfections and infestations0/1404/335
PyelonephritisInfections and infestations0/1404/335
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPlaceboRituximab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders57/140217/335
Infusion related reactionGeneral disorders26/140155/335
Upper respiratory tract infectionInfections and infestations14/140132/335
NasopharyngitisInfections and infestations12/140101/335
Urinary tract infectionInfections and infestations11/14086/335
BronchitisInfections and infestations9/14081/335
FallInjury, poisoning and procedural complications4/14071/335
SinusitisInfections and infestations13/14068/335
Back painMusculoskeletal and connective tissue disorders6/14068/335
HeadacheNervous system disorders7/14061/335

Baseline characteristics

Safety population: All participants who received any part of an infusion of study medication.

Age, Continuous
Age, Continuous(years)Rituximab
Mean53.1 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female273
Male62
08

Study locations

97 sites
  • Mesa, Arizona 85208, United States
  • Paradise Valley, Arizona 85253, United States
  • Tucson, Arizona 85724, United States
  • Little Rock, Arkansas 72205, United States
  • Fullerton, California 92835, United States
  • Los Angeles, California 90045, United States
  • Los Angeles, California 90048, United States
  • Pasadena, California 91105, United States
  • Rancho Mirage, California 92270, United States
  • Santa Maria, California 93454, United States
  • Danbury, Connecticut 06810, United States
  • Boca Raton, Florida 33486, United States
  • Delray Beach, Florida 33484, United States
  • Fort Lauderdale, Florida 33334, United States
  • Jupiter, Florida 33458, United States
  • Orlando, Florida 32806, United States
  • Boise, Idaho 83702, United States
  • Coeur D'alene, Idaho 83814, United States
  • Meridian, Idaho 83642, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202-5149, United States
  • Indianapolis, Indiana 46260, United States
  • Shreverport, Louisiana 71103, United States
  • Baltimore, Maryland 21224, United States
  • Boston, Massachusetts 02215, United States
  • Kalamazoo, Michigan 49048, United States
  • Lansing, Michigan 48910, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63141, United States
  • St Louis, Missouri 63110, United States
  • Albany, New York 12206, United States
  • Manhasset, New York 11030, United States
  • New York, New York 10003, United States
  • Rochester, New York 14618, United States
  • Smithtown, New York 11787, United States
  • Chapel Hill, North Carolina 27599-7600, United States
  • Greenville, North Carolina 27834, United States
  • Cincinnati, Ohio 45267-0563, United States
  • Dayton, Ohio 45402, United States
  • Mayfield, Ohio 44143, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Oklahoma City, Oklahoma 73109, United States
  • Tulsa, Oklahoma 74135, United States
  • Duncansville, Pennsylvania 16635, United States
  • Philadelphia, Pennsylvania 19140, United States
  • Philadelphia, Pennsylvania 19141, United States
  • Philadelphia, Pennsylvania 19152, United States
  • Amarillo, Texas 79124, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77074, United States
  • Waco, Texas 76710, United States
  • Salt Lake City, Utah 84132, United States
  • Burlington, Vermont 05401, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
  • Madison, Wisconsin 53792, United States
  • Bruxelles, 1070, Belgium
  • Bruxelles, 1200, Belgium
  • Gent, 9000, Belgium
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2S2, Canada
  • Hamilton, Ontario L8N 2B6, Canada
  • London, Ontario N6A 4V2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Bois Guillaume, 76233, France
  • Le Kremlin Bicetre, 94275, France
  • Montpellier, 34295, France
  • Paris, 75679, France
  • Toulouse, 31059, France
  • Berlin, 10117, Germany
  • Dresden, 01067, Germany
  • Leipzig, 04103, Germany
  • Ratingen, 40882, Germany
  • Würzburg, 97080, Germany
  • Cork, Ireland
  • Dublin, 4, Ireland
  • Haifa, 3109601, Israel
  • Haifa, 3339419, Israel
  • Jerusalem, 9112001, Israel
  • Petach Tikva, 4941492, Israel
  • Ramat Gan, 5262000, Israel
  • Tel Aviv, 6423906, Israel
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Brescia, Lombardia 25123, Italy
  • Pisa, Toscana 56100, Italy
  • Amsterdam, 1105 AZ, Netherlands
  • Drammen, 3004, Norway
  • Oslo, 0370, Norway
  • Tromsø, 9038, Norway
  • Cannock, WS11 5XY, United Kingdom
  • Leeds, LS7 4SA, United Kingdom
  • London, E11 1NR, United Kingdom
  • Manchester, M41 5SL, United Kingdom
  • Newcastle Upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007 Dec;56(12):3896-908. doi: 10.1002/art.23059. PubMed 18050221 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Mar 27, 2014
Start
Jun 2004
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Nov 7, 2014
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02097745
Lead sponsor
Hoffmann-La Roche
Collaborators
Biogen
Responsible party
Sponsor
First posted
Mar 27, 2014
Start date
Jun 2004
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Nov 7, 2014
Last update
Nov 3, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion